• Publications
  • Influence
Rebound of disease activity during pregnancy after withdrawal of fingolimod
TLDR
This patient presented with severe disease recurrence beginning 11 weeks after the discontinuation of fingolimod, and the recurrence of disease activity might be considered a rebound effect, similar to the immune reconstitution inflammatory syndrome that has been described after cessation of natalizumab therapy. Expand
Rescue Therapy Using Rituximab for Multiple Sclerosis
TLDR
Treatment with rituximab seems to be safe and effective for some patients with relapsing-remitting MS who have failed to respond to first- and second-line therapies and may also be a useful option for patients with concomitant autoimmune disorders. Expand
Switching from natalizumab to fingolimod: an observational study
Multiple sclerosis patients who discontinue using natalizumab are at risk of a rebound in disease activity. However, the optimal alternative therapy is not currently known.
Changes in mechanical, chemical, and thermal sensitivity of the cornea after topical application of nonsteroidal anti-inflammatory drugs.
TLDR
Flurbiprofen had a very limited effect on sensations evokes by corneal stimulation, whereas diclofenac reduced the intensity of sensations evoked by stimuli of different modality, suggesting a mild local anesthetic effect of this drug on all types of corneals sensory fibers. Expand
[Lumbar puncture: its indications, contraindications, complications and technique].
TLDR
The lumbar puncture in expert hands is a safe test, but the health professional should be suitably familiar with its contraindications, the regional anatomy and the technique used to perform it. Expand
Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy
TLDR
The risk of relapse during pregnancy was significantly higher in the group of women treated with natalizumab or fingolimod compared to the group with interferon beta or glatiramer acetate, and the postpartum risk of relapses was lower than that found in previous reports. Expand
Reversible dementia secondary to topiramate.
TLDR
Functional magnetic resonance imaging reveals that topiramate has a critical effect on the cerebral neural systems that mediate expressive language and should be included in the list of drugs associated with dementia, and used with caution in older patients. Expand
Oral BG-12 in multiple sclerosis.
TLDR
It is rather disappointing that the Comparator and an Oral Fumarate in Relapsing–Remitting Multiple Sclerosis (CONFIRM) study, reported by Fox et al., included glatiramer acetate as an active comparison drug but avoided a head-to-head comparison between BG-12 and glatireporter acetate. Expand
Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain
TLDR
Ocrelizumab was generally well-tolerated; the most common adverse events were infusion-related reactions and infections, none of which were serious. Expand
...
1
2
...